The Effect of N115 on Coughing in IPF Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 15, 2023

Primary Completion Date

May 16, 2024

Study Completion Date

May 20, 2024

Conditions
Idiopathic Pulmonary Fibrosis
Interventions
DRUG

20mM sodium pyruvate nasal spray

The product is a 20 mM (0.2%, 2.2 mg/mL) sodium pyruvate nasal spray in 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2 (N115). Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.

OTHER

Saline Placebo control nasal spray

The placebo is 0.9% sodium chloride with benzalkonium chloride preservative, pH 7.2. Subjects will self-administer 3 squirts per nostril of the nasal spray, 3 times daily; upon wakening, noon/midday, and before bedtime.

Trial Locations (1)

33016

Family First Medical Research Center, Hialeah Gardens

Sponsors
All Listed Sponsors
collaborator

Family First Medical Research Center

OTHER

lead

Cellular Sciences, inc.

INDUSTRY

NCT06037408 - The Effect of N115 on Coughing in IPF Patients | Biotech Hunter | Biotech Hunter